QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
uniQure N.V. QURE remains a catalyst-driven gene therapy stock, with AMT-130 shaping most of the investment debate. The program targets Huntington’s disease, an area where disease-modifying options remain absent. Recent FDA feedback, a targeted biologics license application submission in the third quarter of 2026 and …